Panelists discuss how the 8-mg aflibercept formulation improves drying efficacy, extends dosing intervals, and reduces burden while maintaining familiarity for patients across AMD and DME. This ...

Panelists discuss how aflibercept’s structural design and the higher molar dose of its 8-mg formulation enhance VEGF binding, treatment durability, and clinical predictability. The panel reviews why ...

Discover the latest insights on geographic atrophy, its causes, symptoms, and innovative treatment options to manage this eye condition effectively. In this segment, the expert faculty examine a ...

Choroidal dysfunction plays a crucial role in retinal diseases, highlighting its potential as a therapeutic target and the need for innovative treatments. Increasingly, the choroid is being recognized ...

Prof Dr Rajvardhan Azad explains how unified guidelines, AI-driven tools, and cross-disciplinary collaboration could transform outcomes for premature infants. As retinopathy of prematurity (ROP) ...

Ophthalmology advances with AI diagnostics and pediatric trauma insights, merging technology and compassion to enhance patient care and outcomes. From surgical innovations to artificial intelligence ...

Guest lecturer explores the emerging frontiers in ROP therapy and the evolving ethical, clinical, and technological considerations. Retinopathy of prematurity (ROP) remains among the most challenging ...

nAMD treatment options may offer positive outcomes to patients by reducing fluid fluctuations associated with poorer outcomes. To counter this, health care providers often tailor individual treatment ...

Foundation Fighting Blindness releases 4-year RUSH2A data to public ...

In her keynote address, Prof Schmidt-Erfurth focused on new artificial intelligence tools and their usage in addressing age-related macular degeneration. At this year's meeting of the European Society ...

Although my practice is primarily an anterior segment practice, the care of patients with age-related macular degeneration (AMD) is something I have always followed closely. AMD is the leading cause ...

Aviceda Therapeutics has completed enrollment of the phase 2b trial of the SIGLEC Study. The study will assess the safety and efficacy of AVD-104, the company’s formulation designed to treat ...